acute migraine - Robuta Search

https://tjn.org.tr/abstract/1559/eng Use of intranasal lidocain in the treatment of acute migraine | 2002, Volume 8 - Issue 2 | Turkish... in the acute migraine use intranasal lidocain https://ctv.veeva.com/study/a-study-to-evaluate-the-efficacy-and-safety-of-elismetrep-k-304-in-the-acute-treatment-of-migraine?comeFrom=%7B%22type%22%3A%22site%22%2C%22slug%22%3A%22advanced-research-institute-reno-nv%22%7D A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in... a study evaluate efficacy safety acute https://www.satsumarx.com/comparison-of-fda-approved-intranasal-acute-migraine-treatment-adverse-event-profiles/ Comparison of FDA-Approved Intranasal Acute Migraine Treatment Adverse Event Profiles - Satsuma... acute migraine adverse event comparison fda approved https://www.patientcareonline.com/view/novel-dhe-nasal-spray-safe-effective-for-acute-treatment-of-migraine-in-long-term-safety-trial Novel DHE Nasal Spray Safe, Effective For Acute Treatment of Migraine in Long-Term Safety Trial |... Oct 12, 2026 - Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals. nasal spray long term novel dhe safe https://www.prnewswire.com/news-releases/study-compares-nerivio-to-standard-care-medications-for-acute-treatment-of-migraine-in-adolescents-301323048.html Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today... study compares standard care medications https://www.neurologylive.com/view/new-acute-migraine-co-primary-end-points-provide-positives-trial-design New Acute Migraine Co-Primary End Points Provide Positives for Trial Design | NeurologyLive -... Oct 6, 2026 - A review of newly implemented primary end points—pain freedom and most bothersome symptom freedom at 2 hours—used in 8 clinical trials may help to guide future... acute migraine end points new primary provide https://www.neurologylive.com/view/rimegepant-eases-pain-resolves-symptoms-for-acute-migraine Rimegepant Eases Pain, Resolves Symptoms for Acute Migraine | NeurologyLive - Clinical Neurology... Oct 14, 2026 - Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks. acute migraine clinical neurology rimegepant eases pain https://migrainecollaborative.org/papers/the-impact-of-headache-intensity-on-speech-in-participants-with-migraine-and-acute-post-traumatic-headache The impact of headache intensity on speech in participants with migraine and acute post-traumatic... Headache. 2024 Aug 28. doi: 10.1111/head.14809. Online ahead of print. PMID: 39194058 | DOI: 10.1111/head.14809 post traumatic impact headache intensity speech